15 Apr 2021 --- Chr. Hansen is spotlighting the potential of the Asia-Pacific (APAC) market in its Q2 2020/2021 results, which reveal an overall 10 percent organic sales growth in comparison to Q2 2019/2020. Notably, China’s process for allowing human milk oligosaccharides (HMOs) has begun, with the company expecting approvals to come through in around two years. This is a space that has been closely watched by many other global HMO players, such as DSM, which previously flagged COVID-19 could delay the approval process.
